TQB3217Tablets

Phase 1Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB3217Tablets is one of 28 small molecule programs targeting Advanced Malignant Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant TumorsNot yet recruiting

Advanced Malignant TumorsPhase 1

Not yet recruiting

Competition

Competitive Landscape

37 competitors in Advanced Malignant Tumors

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

2 2

Keytruda

Merck & Co.

Phase 2

1 3

Gemzar

Johnson & Johnson

Phase 2

1 4

Rituxan

Roche

Phase 2

1 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 6

Taxotere

AAvyxa

Phase 2

2 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

2 8

Navmi

SSummit Therapeutics

Phase 2

1 9

Paraplatin

AAvyxa

Phase 2

1 10

Opdivo

Bristol-Myers Squibb

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Advanced Malignant Tumors

NCT07291050

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors

Not yet recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT07291050·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TQB3217Tablets. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TQB3217Tablets compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TQB3217Tablets. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB3217Tablets

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced Malignant Tumors1 trial

References

Drug Info

Quick Facts

Related News